FIS Cleared Derivatives Suite Named Post-Trade System of the Year by FOW

Key facts:

  • FIS won first place for the FIS Cleared Derivatives Suite at the FOW International Awards 2021.
  • The FOW awards recognizes excellence and achievements in the derivatives industry.

Financial technology leader FIS ® (NYSE: FIS) today announced that it has won Post-Trade System of the Year at the FOW International Awards 2021 for the FIS Cleared Derivatives Suite . FIS received the award at FOW's (Futures & Options World) ceremony earlier this month.

Judged by a panel of internationally known experts, the FOW International Awards recognizes excellence and achievements in the derivatives industry. Vendors are evaluated on their ability to make significant product enhancements that solve a problem creatively, open new possibilities or change the way participants approach the market.

The FIS Cleared Derivatives Suite is a real-time solution for investment banks and broker dealers that increases the efficiency of post-trade derivative processing. FIS' solution reduces total cost of ownership and operational risk while providing the ability to support new clients and services for middle- and back-office functions. A modular option is available with the suite, allowing companies to try out separate components first.

FIS reimagined the Cleared Derivatives Suite recently to become even more transformational for banks, providing faster responses to industry issues while minimizing migration costs and risks for more than 100 clients. Read about FIS' investments and upgrades to its derivatives solution in this recent article .

"FIS' win at the FOW awards is proof of our investments to continually advance the way the world invests," said Nasser Khodri, head of Capital Markets at FIS. "The FIS Cleared Derivatives Suite provides a modern and efficient real-time global platform that reduces costly integrations, creates better workflows and increases automation. I'm proud that our clients are directly benefiting from a solution that is recognized as the best in its category."

View the list of FOW award winners and read more about the FIS Cleared Derivatives Suite .

About FIS

FIS is a leading provider of technology solutions for merchants, banks and capital markets firms globally. Our employees are dedicated to advancing the way the world pays, banks and invests by applying our scale, deep expertise and data-driven insights. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS ranks #241 on the 2021 Fortune 500 and is a member of Standard & Poor's 500® Index. To learn more, visit www.fisglobal.com . Follow FIS on Facebook , LinkedIn and Twitter ( @FISGlobal ).

Kim Snider, 904.438.6278
Senior Vice President
FIS Global Marketing and Communications
kim.snider@fisglobal.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

GLOBEX MINING ENTERPRISES INC. (GMX Toronto Stock Exchange, G1MN Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exch anges and GLBXF OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (BRW-TSXV, BRWXF-OTCQB) in a press release today, announced additional wide intersections of lithium mineralization on Globex's Lac Escale royalty claims, a part of Brunswick's Mirage property.

Intersections include 36 meters grading 1.51% Li 2 O in Hole MR-24-102 and 1.32% Li 2 O over 28 metres in Hole MR-24-101. A total of 24 drill holes were completed in the winter drill program. Please access Brunswick's press release of today's date for further details.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Latest Press Releases

Related News

×